San Diego, Calif.-based aTyr Pharma has finalized enrollment for a phase 2 trial to evaluate an investigational anti-inflammatory drug in COVID-19 patients with severe respiratory complications.

Coronavirus patients can suffer a form of pneumonia that causes severe respiratory complications which can lead to long-term lung damage. ATYR1923 is meant to reduce inflammation and restore the lung’s immune balance.

The double-blind, placebo-controlled trial, which has 32 participants across the U.S., is designed to evaluate the safety and efficacy of ATYR1923 compared to a placebo. The company plans to release preliminary data by year’s end.